Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory transplant ineligible or progressed after transplant

Relapsed or refractory transplant ineligible or progressed after transplant

Classical Hodgkin lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	13.2 mo	—	52	R 14 921 674 PFS proxy	1
Brentuximab vedotin monotherapy Variant #01	—	R 56 829	21d	8.3 mo	—	17	R 966 097 PFS proxy	1

2 of 2 regimens shown